Contribute Try STAT+ Today

Editor’s note: A recording of the event is embedded below. 

After the biggest meeting in cancer research, sit down with cancer’s biggest decision-maker: the director of the Food and Drug Administration’s Oncology Center of Excellence, who has spent years changing the way cancer drugs are studied and reviewed. What are his thoughts on the latest trends in cancer drug development? Tune in below to find out — and get a chance to ask him your questions.

Featured speakers:

advertisement

  • Sponsor introduction: Jim Weiss, founder & chief executive officer, Real Chemistry
  • Paul Kluetz, M.D., deputy director of the FDA’s Oncology Center of Excellence
  • Rick Pazdur, M.D., director of the FDA’s Oncology Center of Excellence; acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research
  • Harpreet Singh, M.D., associate director for oncology in older adults and special populations in the FDA’s Oncology Center of Excellence; director of the Division of Oncology 2 in the Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA
  • Marc Theoret, M.D., deputy director of the FDA’s Oncology Center of Excellence; acting supervisory associate director of oncology sciences in the Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA
  • Adam Feuerstein, senior writer, biotech, STAT (moderator) 

Create a display name to comment

This name will appear with your comment